At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 63 enrolled
Drug / intervention
LEO 22811 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An International, Multi-centre, Prospective, Randomised, Double-blind, 4-arm, Placebo Controlled, Parallel Group Study With 12 Weeks Once Daily Oral Treatment in Subjects With Psoriasis Vulgaris
In Brief
A Phase 2 clinical trial evaluating LEO 22811 and Placebo for Psoriasis Vulgaris. Completed, enrolled 63 participants across 2 sites in 2 countries.
Detailed Summary
An international, multi-centre, prospective, randomised, double-blind, 4-arm, placebo controlled, parallel group study with 12 weeks once daily oral treatment in subjects with psoriasis vulgaris.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesCanada, France
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedMay 2010
Primary CompletionMar 2011
Study CompletionJul 2011
TodayJul 2026
First PostedMay 5, 2010
Enrollment StartMay 1, 2010
Primary CompletionMar 1, 2011
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 16.2 years ago
Interventions
LEO 22811drug
Oral solution
Placebodrug
Placebo